Press Release List
Hayashibara Announces Plans to Expand Reach in Pullulan Capsules Market
Hayashibara Co., Ltd. Assessment of the “Nature” article, and statement on the safety of TREHA® (trehalose)
Extension of “Okayama Functional Saccharide Plant, T Building” Completed
Construction of an extension to the T Building (Trehalose Manufacturing Plant) of the Okayama Functional Saccharide Plant, which was begun in September of last year, was successfully completed, and a ceremony was held today, September 6, to mark its completion.
U.S. FDA issues GRAS “No Questions Letter” for Isomaltodextrin
Hayashibara Co.,Ltd., a Nagase Group company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has issued a GRAS (generally recognized as safe) "No questions letter", for Hayashibara's new soluble dietary fiber, Isomaltodextrin, qualifying it for safety use in food and beverages.
Extension of “Okayama Functional Saccharide Plant, T Building”
Hayashibara Co., Ltd. have begun construction on an extension to the T Building of the Okayama Functional Saccharide Plant adjacent to the S Building that went into full-scale operation in August.
Operation of a new plant called “Okayama Functional Saccharide Plant, S Building,” and completion of the new Okayama Plant I
Hayashibara Co., Ltd. are in the final stages of a project to relocate the former Okayama Plant I. We have started test operations of the Okayama Functional Saccharide Plant (S Building), and on March 23, we held a ceremony to mark the completion of the new Okayama Plant I.
Strengthening of sales for TREHATM in the U.S. and Europe
ISO 9001 Certification Obtained
The Hayashibara International Art Festival “Rising Stars” Call for Drawings of “Fukuro: Owl Drawings”
Hayashibara Co., Ltd. will hold the Hayashibara International Arts Festival 2013, “Rising Stars,” featuring the “Fukuro: Owl Drawings” exhibition between October 10 (Thursday) and November 9 (Saturday), 2013 under the joint sponsorship of the Cavin-Morris Gallery in New York.
A New Type of Vaccine Adjuvant Which Utilizes Nano-Particle of Pullulan Derivative and Cytokine - A Protective Effects against Influenza Virus Infection have been Confirmed in Animal Experiments -
Hayashibara Co., Ltd. announced that a new effective and stable vaccine adjuvant formulation containing of TNF, a kind of cytokine, pre-encapsulated into nano-particles of pullulan derivatives, has been developed. Intranasal administration of the formulation significantly augmented antibody production of conventional influenza virus and protected mice against lethal influenza virus infection. The formulation would be very convenient because it eventually augmented vaccine effectiveness by nasal administration which has not been applied to the conventional vaccine. Hence, the nano-particle is expected to be a useful tool in the development of an advanced vaccine therapy against various pathogens as well as influenza virus.
Hayashibara will present the results of this research at the 133rd Annual Meeting of the Pharmaceutical Society of Japan (March 27 - 30, at Pacifico Yokohama, Yokohama, Kanagawa Prefecture).